Mostrar el registro sencillo del ítem

Symptomatic and functional outcomes after treatment with paliperidone palmitate 3-month formulation for 52 weeks in patients with clinically stable schizophrenia

dc.contributor.authorGarcía-Portilla González, María Paz 
dc.contributor.authorLlorca, Pierre Michel
dc.contributor.authorMaina, Giuseppe
dc.contributor.authorBozikas, Vasilis P.
dc.contributor.authorDevrimci-Ozguven, Halise
dc.contributor.authorKim, Sung-Wan
dc.contributor.authorBergmans, Paul
dc.contributor.authorUsankova, Irina
dc.contributor.authorPungor, Katalin
dc.date.accessioned2020-09-24T07:43:53Z
dc.date.available2020-09-24T07:43:53Z
dc.date.issued2020
dc.identifier.citationTherapeutic Advances In Psychopharmacology, 10, p. 2045125320926340- (2020); doi:10.1177/2045125320926347
dc.identifier.issn2045-1253
dc.identifier.issn2045-1261
dc.identifier.urihttp://hdl.handle.net/10651/56546
dc.description.sponsorshipJanssenJohnson & Johnson USAJanssen Biotech Inc
dc.format.extentp. 2045125320926340-
dc.language.isoeng
dc.relation.ispartofTherapeutic Advances In Psychopharmacology
dc.rights© 2020 García-Portilla González et al.
dc.rightsCC Reconocimiento - No Comercial 4.0 Internacional
dc.rights.urihttp://creativecommons.org/licenses/by-nc/4.0/
dc.sourceWOS:000537860000001
dc.titleSymptomatic and functional outcomes after treatment with paliperidone palmitate 3-month formulation for 52 weeks in patients with clinically stable schizophrenia
dc.typejournal article
dc.identifier.doi10.1177/2045125320926347
dc.relation.publisherversionhttp://dx.doi.org/10.1177/2045125320926347
dc.rights.accessRightsopen access
dc.type.hasVersionVoR


Ficheros en el ítem

untranslated

Este ítem aparece en la(s) siguiente(s) colección(ones)

Mostrar el registro sencillo del ítem

© 2020 García-Portilla González et al.
Este ítem está sujeto a una licencia Creative Commons